Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma
33,34) Also useful are immunostains for CD10 and Bcl-6, which are positive in follicular lymphoma
and negative in MCL, and CD5, which is positive in MCL, but negative in MALT lymphoma.
Neelapu states, "BiovaxID induces both antibody and T-cell responses against the idiotype (Id), which is the tumor-specific antigen expressed on B-cell lymphomas such as follicular lymphoma
Therapeutics - Products under Development by Companies
Evaluation of interphase fluorescence in situ hybridization for the t(14;18)(q32;q21) translocation in the diagnosis of follicular lymphoma
on fine-needle aspirates: a comparison with flow cytometry immunophenotyping.
, on the other hand, express CD10 but lack CD5 expression.
With longer follow-up, the objective response rate in evaluable patients with CLL/SLL (now 11/14, 79%) and follicular lymphoma
(now 6/13, 46%) improved as compared to December 2010.
18-23] Including our report, to our knowledge, 6 cases of primary follicular lymphoma
of the testis in boys have been reported since 1995.
These results provide long-term support for the exemplary safety and significant benefit demonstrated in three late-stage clinical studies of BiovaxID, including our Phase III controlled, randomized follicular lymphoma
Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma
, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.
The differential diagnosis may include benign lymphoepithelial lesion, nonspecific sialadenitis, cystadenoma lymphomatosum papilliferum, nodal B-cell chronic lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma
, and human immunodeficiency virus-related lymphadenopathy.
This letter, authored by Biovest along with leading clinical oncologists from the MD Anderson Cancer Center and the Abramson Cancer Center at the University of Pennsylvania, explains that BiovaxID is a non-immunosuppressive consolidation therapy and highlights the urgent and unmet need for an autologous active immunotherapy for the treatment of follicular lymphoma
Chapter 4: Elderly Infirm Patient with Advanced Follicular Lymphoma
Vaccine Increases Disease-Free Survival for Follicular Lymphoma
Patients in Phase III Study
Since follicular lymphoma
responds well to therapy and is slow-growing, it is often thought of as a chronic disease.